1
|
Han G, Maruta M, Ikeda Y, Ishikawa T, Tanaka H, Koyama A, Fukuhara R, Boku S, Takebayashi M, Tabira T. Relationship between Performance on the Mini-Mental State Examination Sub-Items and Activities of Daily Living in Patients with Alzheimer's Disease. J Clin Med 2020; 9:E1537. [PMID: 32443659 PMCID: PMC7291070 DOI: 10.3390/jcm9051537] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Revised: 05/14/2020] [Accepted: 05/18/2020] [Indexed: 12/15/2022] Open
Abstract
Mini-mental state examination (MMSE) subitems provide useful information about the cognitive status of patients with Alzheimer's disease (AD). If the relationship between MMSE subitems and activities of daily living (ADL) can be shown, the performance of sub-items can predict ADL status and may provide useful information for early ADL intervention. Therefore, the purpose of this study was to investigate the relationship between MMSE subitem scores and ADL. The study sample consisted of 718 patients with AD. Logistic regression analysis using the Physical Self-maintenance Scale (PSMS) and Lawton's Instrumental ADL (L-IADL) was performed with each of the subitems as the dependent variables and the MMSE subitem as the independent variable. As a result, the subitems of MMSE, which are strongly related to each item in PSMS differed (e.g., toilet: registration odds ratio 3.00, grooming: naming 3.66). In the case of L-IADL, most items were strongly associated with "writing" (e.g., shopping: odds ratio 4.29, laundry 3.83). In clinical practice, we often focus only on the total MMSE score in patients with AD. However, the relationship between each MMSE subitem and ADL suggested in this study may be useful information that can be linked to ADL care from the performance of the MMSE subitem.
Collapse
Affiliation(s)
- Gwanghee Han
- Doctoral Program of Clinical Neuropsychiatry, Graduate School of Health Sciences, Kagoshima University, Kagoshima 890-8544, Japan;
- Department of Neuropsychiatry, Kumamoto University Hospital, Kumamoto 860-8556, Japan; (T.I.); (H.T.); (R.F.); (S.B.); (M.T.)
| | - Michio Maruta
- Doctoral Program of Clinical Neuropsychiatry, Graduate School of Health Sciences, Kagoshima University, Kagoshima 890-8544, Japan;
- Department of Rehabilitation, Medical Corporation Sanshukai, Okatsu Hospital, Kagoshima 890-0067, Japan
| | - Yuriko Ikeda
- Department of Clinical Neuropsychiatry, Graduate School of Health Sciences, Kagoshima University, Kagoshima 890-8544, Japan;
| | - Tomohisa Ishikawa
- Department of Neuropsychiatry, Kumamoto University Hospital, Kumamoto 860-8556, Japan; (T.I.); (H.T.); (R.F.); (S.B.); (M.T.)
| | - Hibiki Tanaka
- Department of Neuropsychiatry, Kumamoto University Hospital, Kumamoto 860-8556, Japan; (T.I.); (H.T.); (R.F.); (S.B.); (M.T.)
| | - Asuka Koyama
- Department of Neuropsychiatry, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan;
| | - Ryuji Fukuhara
- Department of Neuropsychiatry, Kumamoto University Hospital, Kumamoto 860-8556, Japan; (T.I.); (H.T.); (R.F.); (S.B.); (M.T.)
| | - Shuken Boku
- Department of Neuropsychiatry, Kumamoto University Hospital, Kumamoto 860-8556, Japan; (T.I.); (H.T.); (R.F.); (S.B.); (M.T.)
- Department of Neuropsychiatry, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan;
| | - Minoru Takebayashi
- Department of Neuropsychiatry, Kumamoto University Hospital, Kumamoto 860-8556, Japan; (T.I.); (H.T.); (R.F.); (S.B.); (M.T.)
- Department of Neuropsychiatry, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan;
- Division of Psychiatry and Neuroscience, Institute for Clinical Research, National Hospital Organization, Kure Medical Center and Chugoku Cancer Center, Hiroshima 737-0023, Japan
| | - Takayuki Tabira
- Department of Clinical Neuropsychiatry, Graduate School of Health Sciences, Kagoshima University, Kagoshima 890-8544, Japan;
| |
Collapse
|
2
|
Zhang L, Lim CY, Maiti T, Li Y, Choi J, Bozoki A, Zhu DC. Analysis of conversion of Alzheimer’s disease using a multi-state Markov model. Stat Methods Med Res 2018; 28:2801-2819. [DOI: 10.1177/0962280218786525] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
With rapid aging of world population, Alzheimer’s disease is becoming a leading cause of death after cardiovascular disease and cancer. Nearly 10% of people who are over 65 years old are affected by Alzheimer’s disease. The causes have been studied intensively, but no definitive answer has been found. Genetic predisposition, abnormal protein deposits in brain, and environmental factors are suspected to play a role in the development of this disease. In this paper, we model progression of Alzheimer’s disease using a multi-state Markov model to investigate the significance of known risk factors such as age, apolipoprotein E4, and some brain structural volumetric variables from magnetic resonance imaging scans (e.g., hippocampus, etc.) while predicting transitions between different clinical diagnosis states. With the Alzheimer’s Disease Neuroimaging Initiative data, we found that the model with age is not significant (p = 0.1733) according to the likelihood ratio test, but the apolipoprotein E4 is a significant risk factor, and the examination of apolipoprotein E4-by-sex interaction suggests that the apolipoprotein E4 link to Alzheimer’s disease is stronger in women. Given the estimated transition probabilities, the prediction accuracy is as high as 0.7849.
Collapse
Affiliation(s)
- Liangliang Zhang
- Departments of Biostatistics and Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Chae Young Lim
- Department of Statistics, Seoul National University, Seoul, Republic of Korea
| | - Tapabrata Maiti
- Department of Statistics and Probability, Michigan State University, East Lansing, MI, USA
| | - Yingjie Li
- Department of Statistics and Probability, Michigan State University, East Lansing, MI, USA
| | - Jongeun Choi
- School of Mechanical Engineering, Yonsei University, Seoul, Republic of Korea
| | - Andrea Bozoki
- Departments of Neurology and Radiology, Michigan State University, East Lansing, MI, USA
| | - David C. Zhu
- Departments of Radiology and Psychology, Michigan State University, East Lansing, MI, USA
| | | | | |
Collapse
|
3
|
Henneges C, Reed C, Chen YF, Dell'Agnello G, Lebrec J. Describing the Sequence of Cognitive Decline in Alzheimer's Disease Patients: Results from an Observational Study. J Alzheimers Dis 2017; 52:1065-80. [PMID: 27079700 PMCID: PMC4927893 DOI: 10.3233/jad-150852] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Background: Improved understanding of the pattern of cognitive decline in Alzheimer’s disease (AD) would be useful to assist primary care physicians in explaining AD progression to patients and caregivers. Objective: To identify the sequence in which cognitive abilities decline in community-dwelling patients with AD. Methods: Baseline data were analyzed from 1,495 patients diagnosed with probable AD and a Mini-Mental State Examination (MMSE) score ≤ 26 enrolled in the 18-month observational GERAS study. Proportional odds logistic regression models were applied to model MMSE subscores (orientation, registration, attention and concentration, recall, language, and drawing) and the corresponding subscores of the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog), using MMSE total score as the index of disease progression. Probabilities of impairment start and full impairment were estimated at each MMSE total score level. Results: From the estimated probabilities for each MMSE subscore as a function of the MMSE total score, the first aspect of cognition to start being impaired was recall, followed by orientation in time, attention and concentration, orientation in place, language, drawing, and registration. For full impairment in subscores, the sequence was recall, drawing, attention and concentration, orientation in time, orientation in place, registration, and language. The sequence of cognitive decline for the corresponding ADAS-cog subscores was remarkably consistent with this pattern. Conclusion: The sequence of cognitive decline in AD can be visualized in an animation using probability estimates for key aspects of cognition. This might be useful for clinicians to set expectations on disease progression for patients and caregivers.
Collapse
Affiliation(s)
| | - Catherine Reed
- Eli Lilly and Company Limited, Lilly Research Centre, Windlesham, UK
| | | | | | | |
Collapse
|
4
|
Peng D, Shi Z, Xu J, Shen L, Xiao S, Zhang N, Li Y, Jiao J, Wang YJ, Liu S, Zhang M, Wang M, Liu S, Zhou Y, Zhang X, Gu XH, Yang CC, Wang Y, Jiao B, Tang B, Wang J, Yu T, Ji Y. Demographic and clinical characteristics related to cognitive decline in Alzheimer disease in China: A multicenter survey from 2011 to 2014. Medicine (Baltimore) 2016; 95:e3727. [PMID: 27367978 PMCID: PMC4937892 DOI: 10.1097/md.0000000000003727] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/21/2016] [Revised: 03/23/2016] [Accepted: 04/17/2016] [Indexed: 11/28/2022] Open
Abstract
Alzheimer disease (AD) is the most frequent cause of dementia. AD diagnosis, progression, and treatment have not been analyzed nationwide in China. The primary aim of this study was to analyze demographic and clinical characteristics related to cognitive decline in AD patients treated at outpatient clinics in China.We performed a retrospective study of 1993 AD patients at 10 cognitive centers across 8 cities in China from March 2011 to October 2014. Of these, 891 patients were followed for more than 1 year.The mean age at diagnosis was 72.0 ± 10.0 years (range 38-96 years), and the mean age at onset of AD was 69.8 ± 9.5 years. Most patients (65.1%) had moderate to severe symptoms at the time of diagnosis, and mean Mini-Mental State Examination at diagnosis was 15.7 ± 7.7. AD patients showed significant cognitive decline at 12 months after diagnosis. Having more than 9 years of formal education was an independent risk factor related to rapid cognitive decline [odds ratio (OR) = 1.80; 95% confidence interval (95% CI): 1.11-2.91]. Early-onset AD patients experienced more rapid cognitive decline than late-onset patients (OR = 1.83; 95% CI: 1.09-3.06).Most AD patients in China had moderate to severe symptoms at the time of diagnosis and experienced significant cognitive decline within 1 year. Rapid cognitive decline in AD was related to having a higher educational level and younger age of onset.
Collapse
Affiliation(s)
- Dantao Peng
- Department of Neurology, China-Japanese Friendship Hospital, Beijing
| | - Zhihong Shi
- Tianjin Key Laboratory of Cerebrovascular and of neurodegenerative diseases, Tianjin Dementia Institute
- Department of Neurology, Tianjin Huanhu Hospital, Tianjin
| | - Jun Xu
- Department of Neurology, Northern Jiangsu Province Hospital, Affiliated to Yangzhou University, Yangzhou, Jiangsu Province
| | - Lu Shen
- Department of Neurology, Xiangya Hospital, Central South University, Changsha
| | - Shifu Xiao
- Department of Geriatrics, Shanghai Mental Health Center of Shanghai Jiaotong University School of Medicine, Shanghai
| | - Nan Zhang
- Department of neurology, General Hospital of Tianjin Medical University, Tianjin
| | - Yi Li
- Department of Neurology, Qilu Hospital, Shandong university, Shandong
| | - Jinsong Jiao
- Department of Neurology, China-Japanese Friendship Hospital, Beijing
| | - Yan-Jiang Wang
- Department of Neurology and Center for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing
| | - Shuai Liu
- Tianjin Key Laboratory of Cerebrovascular and of neurodegenerative diseases, Tianjin Dementia Institute
- Department of Neurology, Tianjin Huanhu Hospital, Tianjin
| | - Meilin Zhang
- Department of Nutrition and Food Science, School of Public Health, Tianjin Medical University
| | - Meng Wang
- First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin
| | - Shuling Liu
- Tianjin Key Laboratory of Cerebrovascular and of neurodegenerative diseases, Tianjin Dementia Institute
- Department of Neurology, Tianjin Huanhu Hospital, Tianjin
| | - Yuying Zhou
- Tianjin Key Laboratory of Cerebrovascular and of neurodegenerative diseases, Tianjin Dementia Institute
- Department of Neurology, Tianjin Huanhu Hospital, Tianjin
| | - Xiao Zhang
- Department of Neurology, Beijing Hospital, Ministry of Health, Beijing
| | - Xiao-hua Gu
- The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu Province
| | - Ce-ce Yang
- Department of Geriatrics, Shanghai Mental Health Center of Shanghai Jiaotong University School of Medicine, Shanghai
| | - Yu Wang
- Department of Neurology, China-Japanese Friendship Hospital, Beijing
| | - Bin Jiao
- Department of Neurology, Xiangya Hospital, Central South University, Changsha
| | - Beisha Tang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha
| | - Jinhuan Wang
- Tianjin Key Laboratory of Cerebrovascular and of neurodegenerative diseases, Tianjin Dementia Institute
- Department of Neurosurgery, Tianjin Huanhu Hospital, Tianjin, China
| | - Tao Yu
- First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin
| | - Yong Ji
- Tianjin Key Laboratory of Cerebrovascular and of neurodegenerative diseases, Tianjin Dementia Institute
- Department of Neurology, Tianjin Huanhu Hospital, Tianjin
| |
Collapse
|
5
|
Dziedzic T, Pera J, Klimkowicz-Mrowiec A, Mroczko B, Slowik A. Biochemical and Radiological Markers of Alzheimer's Disease Progression. J Alzheimers Dis 2016; 50:623-44. [PMID: 26757184 DOI: 10.3233/ifs-150578] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Alzheimer's disease (AD) is a neurodegenerative, inevitably progressive disease with a rate of cognitive, functional, and behavioral decline that varies highly from patient to patient. Although several clinical predictors of AD progression have been identified, to our mind in clinical practice there is a lack of a reliable biomarker that enables one to stratify the risk of deterioration. Identification of biomarkers that allow the monitoring of AD progression could change the way physicians and caregivers make treatment decisions. This review summarizes the results of studies on potential biochemical and radiological markers related to AD progression.
Collapse
Affiliation(s)
- Tomasz Dziedzic
- Department of Neurology, Jagiellonian University, Krakow, Poland
| | - Joanna Pera
- Department of Neurology, Jagiellonian University, Krakow, Poland
| | | | - Barbara Mroczko
- Department of Neurodegeneration Diagnostics, Medical University of Białystok, Poland.,Department of Biochemical Diagnostics, University Hospital, Białystok, Poland
| | - Agnieszka Slowik
- Department of Neurology, Jagiellonian University, Krakow, Poland
| |
Collapse
|
6
|
Wang B, Tanaka K, Ji B, Ono M, Fang Y, Ninomiya Y, Maruyama K, Izumi-Nakajima N, Begum N, Higuchi M, Fujimori A, Uehara Y, Nakajima T, Suhara T, Nenoi M. Low-dose total-body carbon-ion irradiations induce early transcriptional alteration without late Alzheimer's disease-like pathogenesis and memory impairment in mice. J Neurosci Res 2015; 92:915-26. [PMID: 24936619 DOI: 10.1002/jnr.23363] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The cause and risk factors of Alzheimer's disease (AD) are largely unknown. Studies on possible radiation-induced AD-like pathogenesis and behavioral consequences are important because humans are exposed to ionizing radiation (IR) from various sources. It was reported that total-body irradiations (TBI) at 10 cGy of low linear energy transfer (LET) X-rays to mice triggered acute transcriptional alterations in genes associated with cognitive dysfunctions. However, it was unknown whether low doses of IR could induce AD-like changes late after exposure. We reported previously that 10 cGy X-rays induced early transcriptional response of several AD-related genes in hippocampi without late AD-like pathogenesis and memory impairment in mice. Here, further studies on two low doses (5 or 10 cGy) of high LET carbonion irradiations are reported. On expression of 84 AD-related genes in hippocampi, at 4 hr after TBI, 5 cGy induced a significant upregulation of three genes (Abca1, Casp3, and Chat) and 10 cGy led to a marked upregulation of one gene (Chat) and a downregulation of three genes (Apoe, Ctsd, and Il1α), and, at 1 year after TBI, one gene (Il1α) was significantly downregulated in 10 cGy-irradiated animals. Changes in spatial learning ability and memory and induction of AD-like pathogenesis were not detected by in vivo brain imaging for amyloid-β peptide accumulation and by immunohistochemical staining of amyloid precursor protein, amyloid-β protein, tau, and phosphorylated tau protein. These findings indicate that low doses of carbon-ion irradiations did not cause behavioral impairment or AD-like pathological change in mice.
Collapse
|
7
|
Iarlori S, Ferracuti F, Giantomassi A, Longhi S. RGBD camera monitoring system for Alzheimer's disease assessment using Recurrent Neural Networks with Parametric Bias action recognition. ACTA ACUST UNITED AC 2014. [DOI: 10.3182/20140824-6-za-1003.02199] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
8
|
Ferris SH, Farlow M. Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors. Clin Interv Aging 2013; 8:1007-14. [PMID: 23946647 PMCID: PMC3739421 DOI: 10.2147/cia.s39959] [Citation(s) in RCA: 103] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Alzheimer’s disease is characterized by progressively worsening deficits in several cognitive domains, including language. Language impairment in Alzheimer’s disease primarily occurs because of decline in semantic and pragmatic levels of language processing. Given the centrality of language to cognitive function, a number of language-specific scales have been developed to assess language deficits throughout progression of the disease and to evaluate the effects of pharmacotherapy on language function. Trials of acetylcholinesterase inhibitors, used for the treatment of clinical symptoms of Alzheimer’s disease, have generally focused on overall cognitive effects. However, in the current report, we review data indicating specific beneficial effects of acetylcholinesterase inhibitors on language abilities in patients with Alzheimer’s disease, with a particular focus on outcomes among patients in the moderate and severe disease stages, during which communication is at risk and preservation is particularly important.
Collapse
Affiliation(s)
- Steven H Ferris
- Alzheimer's Disease Center, Comprehensive Center on Brain Aging, New York University Langone Medical Center, New York, NY 10016, USA.
| | | |
Collapse
|
9
|
Weinstein JD, Gonzalez ER, Egleton RD, Hunt DA. A Paradigm Shift for Evaluating Pharmacotherapy for Alzheimer's Disease: The 10-Patient Screening Protocol. ACTA ACUST UNITED AC 2013; 28:443-54. [DOI: 10.4140/tcp.n.2013.443] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
10
|
Chang YL, Bondi MW, McEvoy LK, Fennema-Notestine C, Salmon DP, Galasko D, Hagler DJ, Dale AM. Global clinical dementia rating of 0.5 in MCI masks variability related to level of function. Neurology 2011; 76:652-9. [PMID: 21321338 DOI: 10.1212/wnl.0b013e31820ce6a5] [Citation(s) in RCA: 72] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To evaluate whether ratings on Clinical Dementia Rating (CDR) items related to instrumental activities of daily living (IADL) are associated with cognitive or brain morphometric characteristics of participants with mild cognitive impairment (MCI) and global CDR scores of 0.5. METHODS Baseline cognitive and morphometric data were analyzed for 283 individuals with MCI who were divided into 2 groups (impaired and intact) based on their scores on the 3 CDR categories assessing IADL. Rates of progression to Alzheimer disease (AD) over 2 years were also compared in the 2 groups. RESULTS The impaired IADL MCI group showed a more widespread pattern of gray matter loss involving frontal and parietal regions, worse episodic memory and executive functions, and a higher percentage of individuals progressing to AD than the relatively intact IADL MCI group. CONCLUSIONS The results demonstrate the importance of considering functional information captured by the CDR when evaluating individuals with MCI, even though it is not given equal weight in the assignment of the global CDR score. Worse impairment on IADL items was associated with greater involvement of brain regions beyond the mesial temporal lobe. The conventional practice of relying on the global CDR score as currently computed underutilizes valuable IADL information available in the scale, and may delay identification of an important subset of individuals with MCI who are at higher risk of clinical decline.
Collapse
Affiliation(s)
- Y-L Chang
- Department of Psychology, National Taiwan University, Taipei, 10617 Taiwan.
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Rate of decline in Alzheimer disease measured by a Dementia Severity Rating Scale. Alzheimer Dis Assoc Disord 2010; 23:268-74. [PMID: 19812470 DOI: 10.1097/wad.0b013e318194a324] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To measure clinically relevant change in Alzheimer disease (AD) using a family member-completed Dementia Severity Rating Scale (DSRS) questionnaire. BACKGROUND Measuring rate of change provides important clinical information. Most neuropsychologic scores change nonlinearly, complicating their use as a predictor of change throughout the illness. METHODS DSRS and Mini Mental State scores were prospectively collected on 702 patients with AD from first evaluation until they became too impaired to return to clinic. RESULTS DSRS score increased an average of 4.48 points/y [95% confidence interval (CI): 4.14-4.82] throughout the entire range of severity. In contrast, the Mini Mental State declined an average of 2.15 points/y (95% CI: 1.85-2.46) during the first 2 years, accelerated to 3.83 points/y (95% CI: 3.28-4.38) during the subsequent 3 years, and then slowed to an annual decline of 1.63 points during the last 2 years (95% CI: 0.21-3.05). A younger age of symptom onset was associated with an increased rate of DSRS change (P=0.03). CONCLUSIONS The DSRS provides a clinical measure of functional impairment in AD that increases about 4.48 points/y from the earliest symptomatic stage until patients become too severely impaired to return to clinic.
Collapse
|
12
|
Tandon R, Adak S, Kaye JA. Neural networks for longitudinal studies in Alzheimer's disease. Artif Intell Med 2006; 36:245-55. [PMID: 16427257 DOI: 10.1016/j.artmed.2005.10.007] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2004] [Revised: 10/20/2005] [Accepted: 10/20/2005] [Indexed: 11/18/2022]
Abstract
OBJECTIVE Alzheimer's disease affects a growing population of elderly people today. The predictions about the course of the disease is a key component of health care decision making for patients with Alzheimer's. The physician's prognosis and predicted trajectory of cognitive decline often form the basis of treatment and health care decisions taken by patients and their families. These predictions are difficult to make because of the high variability and non-linearity exhibited by individual patterns of cognitive decline. This paper presents a new method of predicting the course of a disease using longitudinal data collected through multiple clinic visits. Longitudinal databases are similar to temporal databases, with some important differences--data is collected at irregular time intervals that are patient specific and also a varying number of observations are made for each patient, depending upon the number of times the patient visited the clinic. We propose a new type of neural network called the mixed effects neural network (MENN) model that can incorporate this type of longitudinal information. MATERIAL AND METHODS We have used longitudinal data on 704 subjects enrolled at the Layton aging and research center (LAARC) at Oregon Health and Science University. A back-propagation algorithm, modified for longitudinal data is used to obtain the weight parameters of the MENN. The modified back-propagation algorithm is further embedded in an iterative procedure that estimates the noise variance and the parameters that capture the longitudinal (temporal) correlation structure. RESULTS We have compared the performance of the MENN with linear mixed effects models and standard neural networks (NN). MENN show better performance (misclassification rate = 0.13 and relative MSE = 0.35) as compared to standard NN (misclassification rate = 0.34 and relative MSE = 2.74) and linear mixed effects models (misclassification rate = 0.14 and relative MSE = 0.4). CONCLUSION The results show that this method can be a useful tool for predicting non-linear disease trajectories and uncovering significant prognostic factors in longitudinal databases.
Collapse
Affiliation(s)
- Reeti Tandon
- Computational Biology and Biostatistics Lab, GE India Technology Center, EPIP Phase II, Hoodi Village, Whitefield Road, Bangalore, Karnataka 560066, India.
| | | | | |
Collapse
|
13
|
Behl P, Stefurak TL, Black SE. Progress in clinical neurosciences: cognitive markers of progression in Alzheimer's disease. Can J Neurol Sci 2005; 32:140-51. [PMID: 16018149 DOI: 10.1017/s0317167100003917] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The objective of this review is to summarize the literature on Alzheimer's disease progression utilizing cognitive batteries to track change over time. Studies published in English and obtained through PubMed searches (1983-2004) were included (i) if they had a longitudinal design and followed probable Alzheimer's patients diagnosed by National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association or Diagnostic and Statistical Manual III/IV criteria, and (ii) if the techniques used for serial assessment were well-established in terms of validity and reliability. Longitudinal studies examining Alzheimer's disease progression report highly variable annual rates of change in decline rate. It remains unclear if this reflects disease subgroups or stage-related rate of decline. In conclusion a combination of stage-appropriate cognitive tests such as the Mattis Dementia Rating Scale and the Severe Impairment Battery, along with appropriate statistical methods to account for individual variability in decline rates, can capture the progression of Alzheimer disease and may be useful in further investigation.
Collapse
Affiliation(s)
- Pearl Behl
- Linda Campbell Cognitive Neurology Research Unit, Sunnybrook and Women's Research Institute, Toronto, ON, Canada
| | | | | |
Collapse
|